The agreement uses Onegevity multi-omic Artificial Intelligence-powered (AI) platform that also uses genetic and blood biomarker data to decide personalised diet, nutrition, and lifestyle recommendations.
“We are proud to cooperate with Onegevity, which represents an absolute innovation for consumers’ health,” says Daniele Giavini, managing director of Indena.
“Our project with Onegevity is perfectly in line with Indena's approach and with our continuous focus on research and development of highly effective solutions that are synergistic to the Onegevity wellness plan.
“The collaboration will allow us to process certain botanical ingredients out of Indena’s portfolio through the Onegevity AI platform, with the aim of discovering novel potential indications, and beneficial effects for new or known botanical ingredients, as applicable to the pharmaceutical or nutraceutical market. This project fits very well to our credo “Science is our Nature”.
Gutbio and Agebio
Among the tests available through Onegevity are Gutbio, an at-home microbiome test that uses sequencing and artificial intelligence to provide an in-depth look at gut health.
Agebio, another test in the Onegevity suite, assesses the body’s biological age versus its chronological age, and provides personalised supplementation lifestyle and food advice from a scientifically validated blood panel, to keep the body healthy for longer.
Launched in early 2019, the US-based firm has since secured partnerships with food and beverage company Kirin to develop new nutritional products, particularly in the pre- and pro-biotic spaces.
Together with drug discovery firm Tetra Bio-Pharma and health and technology company Thorne, Onegevity formed CB2 Therapeutics back in August 2019, which used multi-omics and multi-targeted therapeutic options to address chronic inflammatory conditions via the endocannabinoid system (ECS).
“We’ve had a long history working with Indena and have found them to be the premier partner for developing plant-based health products and a strong commitment to research,” comments Paul Jacobson, CEO of Onegevity and Thorne.
“One of our partnership goals is to identify effective strategies to reduce the biological age vs. the chronological age of individuals by offering actionable solutions.
“We expect to gain many insights from this compound screening cooperation project to improve personalised solutions for people worldwide.”
Science is our Nature
The deal with Onegevity is in keeping with Indena’s commitment to new approaches for preventive health such as digital healthcare and other alternative health solutions.
The Milan-based firm, which specialise in the identification, development and production of plant-based botanicals for nutraceutical market, entered into agreement signed with Mediatech to implement cloud-based technology to offer customers tailor-made digital services and solutions.
In 2017, Indena entered into a partnership with Hyris, that also uses its AI-driven platform to enable ‘on the edge’ genetic testing in any setting, at any time.
The pact saw Hyris and Indena develop specific identification methods, or DNA barcoding tests, to assure the traceability and identification of botanical raw materials.
